Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEZSNASDAQ:BCABNASDAQ:LSTANASDAQ:OVID On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.22+2.2%$2.92$3.96▼$12.00$5.77M1.557,305 shs2,509 shsBCABBioAtla$0.44-3.4%$0.34$0.24▼$3.53$26.65M1.08982,439 shs810,686 shsLSTALisata Therapeutics$2.53+3.7%$2.26$1.87▼$4.20$21.81M121,289 shs9,602 shsOVIDOvid Therapeutics$0.35+3.0%$0.40$0.24▼$3.45$24.66M0.44448,870 shs634,786 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris+1.29%+11.36%+2.70%+9.00%-60.23%BCABBioAtla-3.44%+36.07%+17.62%-11.81%-81.25%LSTALisata Therapeutics+4.55%+11.95%+7.20%-5.60%-8.66%OVIDOvid Therapeutics+3.00%+20.20%-14.77%-52.74%-88.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEZSAeterna ZentarisN/AN/AN/AN/AN/AN/AN/AN/ABCABBioAtla2.9127 of 5 stars3.33.00.00.02.72.51.3LSTALisata Therapeutics2.9437 of 5 stars3.55.00.00.02.50.01.3OVIDOvid Therapeutics4.5249 of 5 stars3.54.00.04.61.84.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEZSAeterna Zentaris 0.00N/AN/AN/ABCABBioAtla 2.50Moderate Buy$6.001,261.78% UpsideLSTALisata Therapeutics 3.00Buy$15.00492.89% UpsideOVIDOvid Therapeutics 3.00Buy$3.03774.41% UpsideCurrent Analyst Ratings BreakdownLatest AEZS, OVID, BCAB, and LSTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2025OVIDOvid TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/31/2025BCABBioAtlaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/24/2025OVIDOvid TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.003/12/2025OVIDOvid TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $3.001/29/2025OVIDOvid TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$4.00(Data available from 4/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEZSAeterna Zentaris$2.37M2.43N/AN/A$14.99 per share0.21BCABBioAtla$11M2.34N/AN/A$1.47 per share0.30LSTALisata Therapeutics$1M21.81N/AN/A$5.88 per share0.43OVIDOvid Therapeutics$566K43.56N/AN/A$1.24 per share0.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEZSAeterna Zentaris-$16.55M-$14.86N/A∞N/A-760.32%-83.45%-45.76%5/12/2025 (Estimated)BCABBioAtla-$123.46M-$1.44N/AN/AN/AN/A-187.30%-96.33%5/13/2025 (Estimated)LSTALisata Therapeutics-$20.84M-$2.40N/AN/AN/AN/A-51.19%-45.16%5/8/2025 (Estimated)OVIDOvid Therapeutics-$52.34M-$0.38N/AN/AN/A-5,142.56%-39.24%-26.19%5/13/2025 (Estimated)Latest AEZS, OVID, BCAB, and LSTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025BCABBioAtla-$0.28N/AN/AN/AN/AN/A5/13/2025Q1 2025OVIDOvid Therapeutics-$0.14N/AN/AN/A$0.03 millionN/A5/8/2025Q1 2025LSTALisata Therapeutics-$0.53N/AN/AN/AN/AN/A3/27/2025Q4 2024BCABBioAtla-$0.40-$0.32+$0.08-$0.34N/AN/A3/11/2025Q4 2024OVIDOvid Therapeutics-$0.16-$0.13+$0.03-$0.13$0.19 million$0.08 million2/27/2025Q4 2024LSTALisata Therapeutics-$0.76-$0.55+$0.21-$0.55N/A$1.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEZSAeterna ZentarisN/AN/AN/AN/AN/ABCABBioAtlaN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEZSAeterna ZentarisN/A5.945.93BCABBioAtlaN/A3.113.11LSTALisata TherapeuticsN/A8.038.03OVIDOvid Therapeutics0.185.665.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEZSAeterna Zentaris0.73%BCABBioAtla77.23%LSTALisata Therapeutics8.94%OVIDOvid Therapeutics72.24%Insider OwnershipCompanyInsider OwnershipAEZSAeterna Zentaris0.10%BCABBioAtla11.50%LSTALisata Therapeutics9.10%OVIDOvid Therapeutics13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataBCABBioAtla6058.40 million42.79 millionOptionableLSTALisata Therapeutics308.62 million7.63 millionNot OptionableOVIDOvid Therapeutics6071.08 million61.57 millionOptionableAEZS, OVID, BCAB, and LSTA HeadlinesRecent News About These CompaniesOvid Therapeutics Inc. (NASDAQ:OVID) Receives $3.03 Average PT from BrokeragesApril 25 at 1:33 AM | americanbankingnews.comOvid Police Chief, city accused of civil rights violationsApril 24 at 1:12 AM | msn.comOvid Therapeutics (OVID) Receives a Buy from TD CowenApril 23 at 5:06 AM | theglobeandmail.comBiotech Leaders Implore Sen. Cassidy To Step Up in Wake of FDA CutsApril 10, 2025 | biospace.comOvid's Main Street Business Owners Are Speaking Out About Recovery Process After January FireApril 5, 2025 | weny.comOvid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | markets.businessinsider.comNozzolio and NextEra to visit Ovid for donation event after Main Street fireApril 2, 2025 | fingerlakes1.comOvid Therapeutics price target lowered to $2 from $3 at H.C. WainwrightMarch 25, 2025 | markets.businessinsider.comOvid Therapeutics price target lowered to $4 from $5 at BTIGMarch 25, 2025 | markets.businessinsider.comOvid man arrested for failing to register as sex offenderMarch 21, 2025 | fingerlakes1.comOvid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 12, 2025 | finance.yahoo.comWilliam Blair Sticks to Their Buy Rating for Ovid Therapeutics (OVID)March 12, 2025 | markets.businessinsider.comOvid Therapeutics price target lowered to $3 from $4 at WedbushMarch 12, 2025 | markets.businessinsider.comWe're A Little Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn RateMarch 11, 2025 | uk.finance.yahoo.comOvid Therapeutics sees cash runway into 2H26March 11, 2025 | markets.businessinsider.comOvid Therapeutics reports Q4 EPS (13c), consensus (17c)March 11, 2025 | markets.businessinsider.comOvid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue EstimatesMarch 11, 2025 | zacks.comOvid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial ResultsMarch 11, 2025 | globenewswire.comUPDATE: Wanted suspect from Ovid still on the runMarch 9, 2025 | wilx.comOvid Therapeutics appoints new board member and updates compensation policyMarch 7, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 High-Yield Dividend Stocks Trading at a DiscountBy Nathan Reiff | April 14, 2025View 3 High-Yield Dividend Stocks Trading at a DiscountWhich Healthcare Stock Is the Best Buy Right Now?By Nathan Reiff | March 31, 2025View Which Healthcare Stock Is the Best Buy Right Now?3 Safe Dividend Stocks as Investors Seek to Reset DiversificationBy Chris Markoch | April 14, 2025View 3 Safe Dividend Stocks as Investors Seek to Reset Diversification2 High-Yield Values for Dividend Growth and Capital GainsBy Thomas Hughes | April 4, 2025View 2 High-Yield Values for Dividend Growth and Capital GainsBerkshire Hathaway Gains Defy Stock Market Slump By Jeffrey Neal Johnson | April 1, 2025View Berkshire Hathaway Gains Defy Stock Market Slump AEZS, OVID, BCAB, and LSTA Company DescriptionsAeterna Zentaris NASDAQ:AEZS$3.22 +0.07 (+2.22%) As of 04/25/2025Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.BioAtla NASDAQ:BCAB$0.44 -0.02 (-3.44%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.44 -0.01 (-1.27%) As of 04/25/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Lisata Therapeutics NASDAQ:LSTA$2.52 +0.08 (+3.07%) As of 04/25/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Ovid Therapeutics NASDAQ:OVID$0.35 +0.01 (+3.00%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.37 +0.02 (+5.79%) As of 04/25/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
